Breaking Finance News

TESARO Inc (NASDAQ:TSRO) target bumped up to $183.00, released a report earlier today by Oppenheimer Holdings Inc.

Reporting a potential upside of 0.18%, Oppenheimer Holdings Inc. upped the price target of TESARO Inc (NASDAQ:TSRO) to $183.00

Having a price of $155.73, TESARO Inc (NASDAQ:TSRO) traded -2.10% lower on the day. With the last close up -16.63% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. TSRO has recorded a 50-day average of $119.39 and a two hundred day average of $131.99. Trade Volume was down over the average, with 480,616 shares of TSRO changing hands under the typical 809,809

Performance Chart


With a total market value of $0, TESARO Inc has with a one year low of $106.64 and a one year high of $192.94 .

A total of 10 equity analysts have released a ratings update on TSRO. Eight equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About TESARO Inc (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.